The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy

ConclusionsPIV may guide the treatment decision process and the development of novel first-line treatment strategies in melanoma, but warrants further study and validation.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research